248 related articles for article (PubMed ID: 26769917)
1. Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation.
Gannon BM; Williamson A; Suzuki M; Rice KC; Fantegrossi WE
J Pharmacol Exp Ther; 2016 Mar; 356(3):615-23. PubMed ID: 26769917
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.
Fantegrossi WE; Gannon BM; Zimmerman SM; Rice KC
Neuropsychopharmacology; 2013 Mar; 38(4):563-73. PubMed ID: 23212455
[TBL] [Abstract][Full Text] [Related]
3. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.
Baumann MH; Partilla JS; Lehner KR; Thorndike EB; Hoffman AF; Holy M; Rothman RB; Goldberg SR; Lupica CR; Sitte HH; Brandt SD; Tella SR; Cozzi NV; Schindler CW
Neuropsychopharmacology; 2013 Mar; 38(4):552-62. PubMed ID: 23072836
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective Actions of Methylenedioxypyrovalerone (MDPV) To Inhibit Dopamine and Norepinephrine Transporters and Facilitate Intracranial Self-Stimulation in Rats.
Kolanos R; Partilla JS; Baumann MH; Hutsell BA; Banks ML; Negus SS; Glennon RA
ACS Chem Neurosci; 2015 May; 6(5):771-7. PubMed ID: 25688761
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).
Marusich JA; Antonazzo KR; Wiley JL; Blough BE; Partilla JS; Baumann MH
Neuropharmacology; 2014 Dec; 87():206-13. PubMed ID: 24594476
[TBL] [Abstract][Full Text] [Related]
6. Reinforcing effects of abused 'bath salts' constituents 3,4-methylenedioxypyrovalerone and α-pyrrolidinopentiophenone and their enantiomers.
Gannon BM; Rice KC; Collins GT
Behav Pharmacol; 2017 Oct; 28(7):578-581. PubMed ID: 28570297
[TBL] [Abstract][Full Text] [Related]
7. Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice.
Gannon BM; Williamson A; Rice KC; Fantegrossi WE
Neuropharmacology; 2018 May; 134(Pt A):13-21. PubMed ID: 28887185
[TBL] [Abstract][Full Text] [Related]
8. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats.
Aarde SM; Huang PK; Creehan KM; Dickerson TJ; Taffe MA
Neuropharmacology; 2013 Aug; 71():130-40. PubMed ID: 23597511
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent MDPV-induced taste aversions and thermoregulation in adolescent and adult rats.
Merluzzi AP; Hurwitz ZE; Briscione MA; Cobuzzi JL; Wetzell B; Rice KC; Riley AL
Dev Psychobiol; 2014 Jul; 56(5):943-54. PubMed ID: 24122728
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic Effects of Major Bath Salt Constituents 3,4-Methylenedioxypyrovalerone (MDPV), Mephedrone, and Methylone Are Enhanced Following Co-exposure.
Allen SA; Tran LH; Oakes HV; Brown RW; Pond BB
Neurotox Res; 2019 Jul; 36(1):132-143. PubMed ID: 30879275
[TBL] [Abstract][Full Text] [Related]
11. Chiral resolution and absolute configuration of the enantiomers of the psychoactive "designer drug" 3,4-methylenedioxypyrovalerone.
Suzuki M; Deschamps JR; Jacobson AE; Rice KC
Chirality; 2015 Apr; 27(4):287-93. PubMed ID: 25727807
[TBL] [Abstract][Full Text] [Related]
12. Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects.
Anizan S; Concheiro M; Lehner KR; Bukhari MO; Suzuki M; Rice KC; Baumann MH; Huestis MA
Addict Biol; 2016 Mar; 21(2):339-47. PubMed ID: 25475011
[TBL] [Abstract][Full Text] [Related]
13. 3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.
Magee CP; German CL; Siripathane YH; Curtis PS; Anderson DJ; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2020 Aug; 374(2):273-282. PubMed ID: 32385092
[TBL] [Abstract][Full Text] [Related]
14. Effects of social interaction and warm ambient temperature on brain hyperthermia induced by the designer drugs methylone and MDPV.
Kiyatkin EA; Kim AH; Wakabayashi KT; Baumann MH; Shaham Y
Neuropsychopharmacology; 2015 Jan; 40(2):436-45. PubMed ID: 25074640
[TBL] [Abstract][Full Text] [Related]
15. Non-conserved residues dictate dopamine transporter selectivity for the potent synthetic cathinone and psychostimulant MDPV.
Steele TWE; Spires Z; Jones CB; Glennon RA; Dukat M; Eltit JM
Neuropharmacology; 2021 Dec; 200():108820. PubMed ID: 34619165
[TBL] [Abstract][Full Text] [Related]
16. Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP).
Glennon RA; Young R
Brain Res Bull; 2016 Sep; 126(Pt 1):111-126. PubMed ID: 27142261
[TBL] [Abstract][Full Text] [Related]
17. Changes in CREB and deltaFosB are associated with the behavioural sensitization induced by methylenedioxypyrovalerone.
Buenrostro-Jáuregui M; Ciudad-Roberts A; Moreno J; Muñoz-Villegas P; López-Arnau R; Pubill D; Escubedo E; Camarasa J
J Psychopharmacol; 2016 Jul; 30(7):707-12. PubMed ID: 27147595
[TBL] [Abstract][Full Text] [Related]
18. Contribution of monoaminergic mechanisms to the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone (MDPV) in Sprague-Dawley rats.
Risca HI; Baker LE
Psychopharmacology (Berl); 2019 Mar; 236(3):963-971. PubMed ID: 30554256
[TBL] [Abstract][Full Text] [Related]
19. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV).
Watterson LR; Kufahl PR; Nemirovsky NE; Sewalia K; Grabenauer M; Thomas BF; Marusich JA; Wegner S; Olive MF
Addict Biol; 2014 Mar; 19(2):165-74. PubMed ID: 22784198
[TBL] [Abstract][Full Text] [Related]
20. In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats.
Aarde SM; Creehan KM; Vandewater SA; Dickerson TJ; Taffe MA
Psychopharmacology (Berl); 2015 Aug; 232(16):3045-55. PubMed ID: 25925780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
